Opportunity emerges at nexus of regenerative medicine, medical device segments
Morning, healthcare fanatics!
I’m off for a quick vacay tomorrow. Will be largely out of pocket through next Thursday as I enjoy nature and good eats far from the city.
But before I sign off, let me highlight some of the week’s deal news … ICYMI: I learned about two that quietly transacted earlier this year: Blue Wolf Capital snapped up Fox Rehab after a formal sales process for the company stalled. Separately, BlueMountain Capital recapitalized QMES, one of a handful of durable-medical-equipment processes I wrote about in 2018.
Meanwhile, Arsenal — whose healthcare bets have historically involved outsourcing services that serve the life sciences industry or other providers — made its first behavioral health deal. Read my story to find out where its deal for Hopebridge valued the autism-treatment company.
An interesting side note: John DiGiovanni joined Arsenal as a principal earlier this year from Baird Capital, Hopebridge’s existing investor, which will reinvest.
As for brewing deal activity…
New(ish) on the block
Metalmark Capital is evaluating the sale of Collagen Matrix, a medical device company focused on regenerative medicine.
Read my full story for deets on which banks are involved, how far along the process is and what kind of pricetag the company could command.
SUBSCRIBE to get the Healthcare Wire in your inbox every Thursday morning. It’s free!
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.